Anne Vessieres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4332167/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2022, 60, 100788.	6.5	15
2	Multifaceted chemical behaviour of metallocene (MÂ=ÂFe, Os) quinone methides. Their contribution to biology. Coordination Chemistry Reviews, 2021, 430, 213658.	9.5	33
3	Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes. International Journal of Molecular Sciences, 2021, 22, 10404.	1.8	11
4	Small Structural Differences between Two Ferrocenyl Diphenols Determine Large Discrepancies of Reactivity and Biological Effects. ChemMedChem, 2019, 14, 1717-1726.	1.6	17
5	Intracellular Localization of an Osmocenylâ€Tamoxifen Derivative in Breast Cancer Cells Revealed by Synchrotron Radiation Xâ€ray Fluorescence Nanoimaging. Angewandte Chemie - International Edition, 2019, 58, 3461-3465.	7.2	25
6	Intracellular Localization of an Osmocenylâ€Tamoxifen Derivative in Breast Cancer Cells Revealed by Synchrotron Radiation Xâ€ray Fluorescence Nanoimaging. Angewandte Chemie, 2019, 131, 3499-3503.	1.6	11
7	New mechanistic insights into osmium-based tamoxifen derivatives. Electrochimica Acta, 2019, 302, 130-136.	2.6	3
8	CHAPTER 3. Iron Compounds as Anticancer Agents. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 62-90.	0.8	7
9	Ferrocifens labelled with an infrared rhenium tricarbonyl tag: synthesis, antiproliferative activity, quantification and nano IR mapping in cancer cells. Dalton Transactions, 2018, 47, 9824-9833.	1.6	20
10	Approach to ferrocenyl-podophyllotoxin analogs and their evaluation as anti-tumor agents. Journal of Organometallic Chemistry, 2017, 839, 83-90.	0.8	19
11	Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse. Pharmacological Research, 2017, 126, 54-65.	3.1	37
12	Tamoxifen-like metallocifens target the thioredoxin system determining mitochondrial impairment leading to apoptosis in Jurkat cells. Metallomics, 2017, 9, 949-959.	1.0	30
13	Side-Chain Effects on the 1-(Bis-aryl-methylidene)-[3]ferrocenophane Skeleton: Antiproliferative Activity against TNBC Cancer Cells and Comparison with the Acyclic Ferrocifen Series. European Journal of Inorganic Chemistry, 2017, 2017, 454-465.	1.0	6
14	Ferrocenyl Quinone Methide–Thiol Adducts as New Antiproliferative Agents: Synthesis, Metabolic Formation from Ferrociphenols, and Oxidative Transformation. Angewandte Chemie, 2016, 128, 10587-10590.	1.6	10
15	Ferrocenyl Quinone Methide–Thiol Adducts as New Antiproliferative Agents: Synthesis, Metabolic Formation from Ferrociphenols, and Oxidative Transformation. Angewandte Chemie - International Edition, 2016, 55, 10431-10434.	7.2	33
16	Enzymatic oxidation of ansa-ferrocifen leads to strong and selective thioredoxin reductase inhibition in vitro. Journal of Inorganic Biochemistry, 2016, 165, 146-151.	1.5	19
17	Osmocenyl-tamoxifen derivatives target the thioredoxin system leading to a redox imbalance in Jurkat cells. Journal of Inorganic Biochemistry, 2016, 160, 296-304.	1.5	21
18	Oxidative Metabolism of Ferrocene Analogues of Tamoxifen: Characterization and Antiproliferative Activities of the Metabolites. ChemMedChem, 2015, 10, 981-990.	1.6	33

#	Article	IF	CITATIONS
19	Synthesis, Characterization, and Biological Properties of Osmiumâ€Based Tamoxifen Derivatives – Comparison with Their Homologues in the Iron and Ruthenium Series. European Journal of Inorganic Chemistry, 2015, 2015, 4217-4226.	1.0	32
20	Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules. International Journal of Nanomedicine, 2015, 10, 1259.	3.3	21
21	Ferrocifen type anti cancer drugs. Chemical Society Reviews, 2015, 44, 8802-8817.	18.7	462
22	Cytotoxic Triosmium Carbonyl Clusters: A Structure–Activity Relationship Study. ChemMedChem, 2014, 9, 1453-1457.	1.6	22
23	Quantitative Analyses of ROS and RNS Production in Breast Cancer Cell Lines Incubated with Ferrocifens. ChemMedChem, 2014, 9, 1286-1293.	1.6	46
24	Evidence for Targeting Thioredoxin Reductases with Ferrocenyl Quinone Methides. A Possible Molecular Basis for the Antiproliferative Effect of Hydroxyferrocifens on Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 8849-8859.	2.9	102
25	Synthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells. Dalton Transactions, 2014, 43, 817-830.	1.6	27
26	Ferrocifen derivatives that induce senescence in cancer cells: selected examples. Journal of Inorganic Biochemistry, 2014, 141, 144-151.	1.5	56
27	Influence of the Sideâ€Chain Length on the Cellular Uptake and the Cytotoxicity of Rhenium Triscarbonyl Derivatives: A Bimodal Infrared and Luminescence Quantitative Study. Chemistry - A European Journal, 2014, 20, 8714-8722.	1.7	64
28	Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1667-1677.	1.7	38
29	Synchrotron radiation FTIR detection of a metal-carbonyl tamoxifen analog. Correlation with luminescence microscopy to study its subcellular distribution. Biotechnology Advances, 2013, 31, 393-395.	6.0	41
30	The inÂvivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer. Biomaterials, 2013, 34, 6949-6956.	5.7	43
31	Ferrocenyl flavonoid-induced morphological modifications of endothelial cells and cytotoxicity against B16 murine melanoma cells. Journal of Organometallic Chemistry, 2013, 734, 78-85.	0.8	28
32	Metal carbonyl tracers and the ferrocifen family: Two facets of bioorganometallic chemistry. Journal of Organometallic Chemistry, 2013, 734, 3-16.	0.8	39
33	Detection of an estrogen derivative in two breast cancer cell lines using a single core multimodal probe for imaging (SCoMPI) imaged by a panel of luminescent and vibrational techniques. Analyst, The, 2013, 138, 5627.	1.7	75
34	Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen–SAHA hybrids and related species. Dalton Transactions, 2013, 42, 15489.	1.6	34
35	Synthesis and antiproliferative evaluation of ferrocenyl and cymantrenyl triaryl butene on breast cancer cells. Biodistribution study of the corresponding technetium-99m tamoxifen conjugate. Journal of Organometallic Chemistry, 2013, 734, 69-77.	0.8	25
36	Surface grafting of a ï€-conjugated amino-ferrocifen drug. Journal of Electroanalytical Chemistry, 2013, 699, 21-27.	1.9	9

#	Article	IF	CITATIONS
37	In vitro inhibitory properties of ferrocene-substituted chalcones and aurones on bacterial and human cell cultures. Dalton Transactions, 2012, 41, 6451.	1.6	59
38	Recent Applications of Molecular Spectroscopy in Bioorganometallic Chemistry–Part 2: Ferrocenes and Other Organometallic Complexes. Applied Spectroscopy Reviews, 2012, 47, 620-632.	3.4	7
39	Recent Analytical Applications of Molecular Spectroscopy in Bioorganometallic Chemistry—Part I: Metal Carbonyls. Applied Spectroscopy Reviews, 2012, 47, 531-549.	3.4	12
40	Ferrocenyl catechols: synthesis, oxidation chemistry and anti-proliferative effects on MDA-MB-231 breast cancer cells. Dalton Transactions, 2012, 41, 7537.	1.6	45
41	Synthesis and Antiproliferative Effects of [3]Ferrocenophane Transposition Products and Pinacols Obtained from McMurry Cross-Coupling Reactions. Organometallics, 2012, 31, 5856-5866.	1.1	20
42	Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 690-693.	2.0	46
43	Patterns of pulmonary tuberculosis on FDG-PET/CT. European Journal of Radiology, 2012, 81, 2872-2876.	1.2	60
44	A new bioorthogonal cross-linker with alkyne and hydrazide end groups for chemoselective ligation. Application to antibody labelling. Tetrahedron, 2012, 68, 9638-9644.	1.0	7
45	A rhenium tris-carbonyl derivative as a single core multimodal probe for imaging (SCoMPI) combining infrared and luminescent properties. Chemical Communications, 2012, 48, 7729.	2.2	94
46	Deciphering the Activation Sequence of Ferrociphenol Anticancer Drug Candidates. Chemistry - A European Journal, 2012, 18, 6581-6587.	1.7	75
47	Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. International Journal of Pharmaceutics, 2012, 423, 55-62.	2.6	36
48	Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. International Journal of Pharmaceutics, 2012, 423, 63-68.	2.6	48
49	Reacting with Cp*Rh Complexes that involve i (sup>1-N, i (sup>2-N, O, i (sup>1-O, and i (sup>6 Bonding Modes, via a Novel N-i Rearrangement; Relative Binding Affinities and Computer Docking Studies of <i>Cis and Trans</i> -i (sup>6-Cp*Rh-Hydroxytamoxifen Complexes at the Estrogen FRi+ and FRi2 Recentors, and Growth Inhibition to Breast Cancer Cells, Inorganic Chemistry	1.9	20
50	2011, 50, 271-284. A new series of ferrocifen derivatives, bearing two aminoalkyl chains, with strong antiproliferative effects on breast cancer cells. New Journal of Chemistry, 2011, 35, 2212.	1.4	38
51	Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cells. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6195-6197.	1.0	30
52	Treatment of 9L Gliosarcoma in Rats by Ferrociphenol-Loaded Lipid Nanocapsules Based on a Passive Targeting Strategy via the EPR Effect. Pharmaceutical Research, 2011, 28, 3189-3198.	1.7	62
53	Subcellular IR Imaging of a Metal–Carbonyl Moiety Using Photothermally Induced Resonance. Angewandte Chemie - International Edition, 2011, 50, 860-864.	7.2	134
54	Evaluation of bactericidal and fungicidal activity of ferrocenyl or phenyl derivatives in the diphenyl butene series. Journal of Organometallic Chemistry, 2011, 696, 1038-1048.	0.8	45

#	Article	IF	CITATIONS
55	Synthesis and biological activity of ferrocenyl derivatives of the non-steroidal antiandrogens flutamide and bicalutamide. Journal of Organometallic Chemistry, 2011, 696, 1049-1056.	0.8	18
56	Local Delivery of Ferrociphenol Lipid Nanocapsules Followed by External Radiotherapy as a Synergistic Treatment Against Intracranial 9L Glioma Xenograft. Pharmaceutical Research, 2010, 27, 56-64.	1.7	54
57	Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene and [3]Ferrocenophane Tetrasubstituted Olefin Derivatives against Human Cancer Cells. ChemMedChem, 2010, 5, 2039-2050.	1.6	76
58	A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen receptor-independent mechanism of action in breast cancer cell lines. Journal of Inorganic Biochemistry, 2010, 104, 503-511.	1.5	68
59	Organometallic SERMs (selective estrogen receptor modulators): Cobaltifens, the (cyclobutadiene)cobalt analogues of hydroxytamoxifen. Journal of Organometallic Chemistry, 2010, 695, 595-608.	0.8	24
60	Comparative toxicity of [3]ferrocenophane and ferrocene moieties on breast cancer cells. Tetrahedron Letters, 2010, 51, 118-120.	0.7	54
61	Site-specific conjugation of metal carbonyl dendrimer to antibody and its use as detection reagent in immunoassay. Analytical Biochemistry, 2010, 407, 211-219.	1.1	34
62	Ferrocene Functionalized Endocrine Modulators as Anticancer Agents. Topics in Organometallic Chemistry, 2010, , 81-117.	0.7	112
63	Organometallic cyclic polyphenols derived from 1,2-(α-keto tri or tetra methylene) ferrocene show strong antiproliferative activity on hormone-independent breast cancer cells. Dalton Transactions, 2010, 39, 7444.	1.6	23
64	Facile synthesis and strong antiproliferative activity of disubstituted diphenylmethylidenyl-[3]ferrocenophanes on breast and prostate cancer cell lines. MedChemComm, 2010, 1, 149.	3.5	36
65	Synthesis and Structure–Activity Relationships of Ferrocenyl Tamoxifen Derivatives with Modified Side Chains. Chemistry - A European Journal, 2009, 15, 684-696.	1.7	58
66	Ferrocenyl Quinone Methides as Strong Antiproliferative Agents: Formation by Metabolic and Chemical Oxidation of Ferrocenyl Phenols. Angewandte Chemie - International Edition, 2009, 48, 9124-9126.	7.2	170
67	Further insights into hydrophobic interactions between ferrocenyl-tamoxifen drugs and non-polar molecular architectures at electrode surfaces. Journal of Electroanalytical Chemistry, 2009, 635, 13-19.	1.9	20
68	Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model. International Journal of Pharmaceutics, 2009, 379, 317-323.	2.6	55
69	Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines. Inorganica Chimica Acta, 2009, 362, 4037-4042.	1.2	22
70	The replacement of a phenol group by an aniline or acetanilide group enhances the cytotoxicity of 2-ferrocenyl-1,1-diphenyl-but-l-ene compounds against breast cancer cells. Journal of Organometallic Chemistry, 2009, 694, 895-901.	0.8	65
71	Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs. Journal of Organometallic Chemistry, 2009, 694, 874-879.	0.8	43
72	Synthesis and Structure Activity Relationship of Organometallic Steroidal Androgen Derivatives. Organometallics, 2009, 28, 1414-1424.	1.1	65

#	Article	IF	CITATIONS
73	Synthesis, oxidation chemistry and cytotoxicity studies on ferrocene derivatives of diethylstilbestrol. Dalton Transactions, 2009, , 10871.	1.6	36
74	A [3]Ferrocenophane Polyphenol Showing a Remarkable Antiproliferative Activity on Breast and Prostate Cancer Cell Lines. Journal of Medicinal Chemistry, 2009, 52, 4964-4967.	2.9	125
75	Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds. Dalton Transactions, 2009, , 4318.	1.6	28
76	Reactivity and Antiproliferative Activity of Ferrocenyl–Tamoxifen Adducts with Cyclodextrins against Hormoneâ€independent Breast ancer Cell Lines. Chemistry - A European Journal, 2008, 14, 8195-8203.	1.7	75
77	Ferrocenyl compounds possessing protected phenol and thiophenol groups: Synthesis, X-ray structure, and in vitro biological effects against breast cancer. Journal of Organometallic Chemistry, 2008, 693, 1716-1722.	0.8	40
78	Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines. Journal of Inorganic Biochemistry, 2008, 102, 1980-1985.	1.5	65
79	Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment. International Journal of Pharmaceutics, 2008, 347, 128-135.	2.6	61
80	Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. Journal of Controlled Release, 2008, 130, 146-153.	4.8	113
81	Synthesis and Structure–Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide. Journal of Medicinal Chemistry, 2008, 51, 1791-1799.	2.9	93
82	Ferrocifens and Ferrocifenols as New Potential Weapons against Breast Cancer. Chimia, 2007, 61, 716.	0.3	152
83	Antiproliferative cardenolides from Periploca graeca. Planta Medica, 2007, 73, 384-387.	0.7	28
84	The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif. Dalton Transactions, 2007, , 5073.	1.6	83
85	Design of a New Multifunctionalized PAMAM Dendrimer with Hydrazide-Terminated Spacer Arm Suitable for Metalâ^Carbonyl Multilabeling of Aldehyde-Containing Molecules. Macromolecules, 2007, 40, 8568-8575.	2.2	27
86	The Use of Glycidol to Introduce Aldehyde Functions Into Proteins – Application to the Fluorescent Labelling of Bovine Serum Albumin and Avidin. European Journal of Organic Chemistry, 2007, 2007, 5429-5433.	1.2	4
87	Organometallic diphenols: The importance of the organometallic moiety on the expression of a cytotoxic effect on breast cancer cells. Journal of Organometallic Chemistry, 2007, 692, 1315-1326.	0.8	66
88	Organometallic analogues of tamoxifen: Effect of the amino side-chain replacement by a carbonyl ferrocenyl moiety in hydroxytamoxifen. Journal of Organometallic Chemistry, 2007, 692, 1219-1225.	0.8	46
89	Organometallics Targeted to Specific Biological Sites: the Development of New Therapies. , 2006, , 65-95.		18

90 Organometallic Complexes as Tracers in Non-isotopic Immunoassay. , 2006, , 263-302.

16

#	Article	IF	CITATIONS
91	Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Transactions, 2006, , 529-541.	1.6	173
92	Synthesis of Optically Pureo-Formylcyclopentadienyl Metal Complexes of 17α-Ethynylestradiol. Recognition of the Planar Chirality by the Estrogen Receptor. Organometallics, 2006, 25, 5730-5739.	1.1	47
93	New Synthetic Pathways ofcis- ortrans-Hydroxytamoxifen Derivatives with in Situ Formed [Cp*Rh(solvent)3]2+Complexes:Â Kinetic and Thermodynamic Control, Including a Novel, Intramolecular N-i€ Rearrangement, and Relative Binding Affinities of the Î-6Complexes for the Estrogen Receptor, Organometallics, 2006, 25, 3293-3296.	1.1	10
94	Organometallic cluster analogues of tamoxifen: Synthesis and biochemical assay. Journal of Organometallic Chemistry, 2006, 691, 9-19.	0.8	16
95	Ferrocene-Mediated Proton-Coupled Electron Transfer in a Series of Ferrocifen-Type Breast-Cancer Drug Candidates. Angewandte Chemie - International Edition, 2006, 45, 285-290.	7.2	373
96	A Series of Unconjugated Ferrocenyl Phenols: Prospects as Anticancer Agents. ChemMedChem, 2006, 1, 551-559.	1.6	109
97	The Presence of a Ferrocenyl Unit on an Estrogenic Molecule is Not Always Sufficient to Generate inâ€vitro Cytotoxicity. ChemMedChem, 2006, 1, 1275-1281.	1.6	33
98	FACS analysis of oxidative stress induced on tumour cells by SERMs. Inorganica Chimica Acta, 2005, 358, 1993-1998.	1.2	36
99	Modification of the Estrogenic Properties of Diphenols by the Incorporation of Ferrocene. Generation of Antiproliferative Effects in Vitro. Journal of Medicinal Chemistry, 2005, 48, 3937-3940.	2.9	200
100	Selective Estrogen Receptor Modulators in the Ruthenocene Series. Synthesis and Biological Behavior. Journal of Medicinal Chemistry, 2005, 48, 2814-2821.	2.9	109
101	The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer. Current Medicinal Chemistry, 2004, 11, 2505-2517.	1.2	252
102	Specific binding of a biotinylated, metallocarbonyl-labelled dendrimer to immobilized avidin detected by diffuse-reflectance infrared Fourier transform spectroscopy. Applied Organometallic Chemistry, 2004, 18, 105-110.	1.7	6
103	Synthesis of Metal-Carbonyl-Dendrimer-Antibody Immunoconjugates: Towards a New Format for Carbonyl Metallo Immunoassay. ChemBioChem, 2004, 5, 519-525.	1.3	31
104	Selective Estrogen-Receptor Modulators (SERMs) in the Cyclopentadienylrhenium Tricarbonyl Series: Synthesis and Biological Behaviour. ChemBioChem, 2004, 5, 1104-1113.	1.3	66
105	Platinum(II) and technetium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery. Inorganica Chimica Acta, 2004, 357, 2157-2166.	1.2	40
106	Synthesis of benzyl- and benzhydrylferrocenes via Friedel–Crafts alkylation of ferrocene. Access to ferrocenyl bisphenols with high affinities for estrogen receptors. Tetrahedron Letters, 2004, 45, 5425-5427.	0.7	13
107	Preparation and characterization of poly(amidoamine) dendrimers functionalized with a rhenium carbonyl complex and PEG as new IR probes for carbonyl metallo immunoassay. Journal of Organometallic Chemistry, 2004, 689, 4775-4782.	0.8	62
108	Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour. ChemBioChem, 2003, 4, 754-761.	1.3	54

#	Article	IF	CITATIONS
109	Synthesis, Biochemical Properties and Molecular Modelling Studies of Organometallic Specific Estrogen Receptor Modulators (SERMs), the Ferrocifens and Hydroxyferrocifens: Evidence for an Antiproliferative Effect of Hydroxyferrocifens on both Hormone-Dependent and Hormone-Independent Breast Cancer Cell Lines. Chemistry - A European Journal, 2003, 9, 5223-5236.	1.7	379
110	Synthesis, Receptor Binding, Molecular Modeling, and Proliferative Assays of a Series of 17α-Arylestradiols. ChemBioChem, 2003, 4, 494-503.	1.3	13
111	Modification of the Cp′ ring in the ferrocifen precursor and its influence on the recognition by the estrogen receptor. Tetrahedron Letters, 2003, 44, 2749-2751.	0.7	17
112	Evaluation of the carbonyl metallo immunoassay (CMIA) for the determination of traces of the herbicide atrazine. Journal of Organometallic Chemistry, 2003, 668, 59-66.	0.8	23
113	Novel Estradiol Derivatives Labeled with Ru, W, and Co Complexes. Influence on Hormone-Receptor Affinity of Several Organometallic Groups at the 17 Position. Chemistry - A European Journal, 2002, 8, 5241-5249.	1.7	43
114	The Hexacarbonyl(ethyne)dicobalt Unit: An Androgen Tag. Helvetica Chimica Acta, 2002, 85, 2918-2925.	1.0	16
115	First carbonyl metallo immunoassay in the environmental area: application to the herbicide chlortoluron. Applied Organometallic Chemistry, 2002, 16, 669-674.	1.7	11
116	First anti-oestrogen in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and study of antiproliferative effects. Chemical Communications, 2001, , 383-384.	2.2	67
117	Studies on organometallic selective estrogen receptor modulators. (SERMs) Dual activity in the hydroxy-ferrocifen series. Journal of Organometallic Chemistry, 2001, 637-639, 500-506.	0.8	235
118	First attachment of the stable organometallic moiety 〚Re(CO) 3 (η 5 -C 5 H 4 –C≡C–)〛 at position 1 oestradiol. Biochemical behaviour of the complex. Comptes Rendus De L'Academie Des Sciences - Series Ilc: Chemistry, 2001, 4, 201-205.	1ß of 0.1	2
119	The Ferrocenylethynyl Unit: a Stable Hormone Tag. Helvetica Chimica Acta, 2001, 84, 3289-3298.	1.0	38
120	The first organometallic antioestrogens and their antiproliferative effects. Comptes Rendus De L'Academie Des Sciences - Series IIc: Chemistry, 2000, 3, 89-93.	0.1	27
121	New paradigms for synthetic pathways inspired by bioorganometallic chemistry. Journal of Organometallic Chemistry, 2000, 600, 23-36.	0.8	130
122	The Co3(CO)9C moiety acts as an electroreducible marker for estradiol detection enhancement in the HPLC-ED technique. Journal of Organometallic Chemistry, 2000, 593-594, 232-239.	0.8	7
123	The first organometallic derivative of 11β-ethynylestradiol, a potential high-affinity marker for the estrogen receptor. Journal of Organometallic Chemistry, 2000, 596, 242-247.	0.8	21
124	New and efficient routes to CpRe(CO)3 substituted steroids. Chemical Communications, 2000, , 211-212.	2.2	17
125	A new application of bioorganometallics: the first simultaneous triple assay by the carbonylmetalloimmunoassay (CMIA) method. Journal of Organometallic Chemistry, 1999, 589, 92-97.	0.8	51
126	Carbonyl metallo immuno assay: a new application for Fourier transform infrared spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 1999, 21, 625-633.	1.4	64

#	Article	IF	CITATIONS
127	Synthesis of CpFe(CO)(L) Complexes of Hydantoin Anions (Cp = η5-C5H5, L = CO, PPh3), and the Use of the 5,5-Diphenylhydantoin Anion Complexes as Tracers in the Nonisotopic Immunoassay CMIA of This Antiepileptic Drug. Bioconjugate Chemistry, 1999, 10, 379-385.	1.8	27
128	Optimization of Two Fourier Transform Infrared Least-Squares Multivariate Analysis Methods for the Simultaneous Quantitation of Mixtures of Three Metal-Carbonyl Complexes in the Picomole Range. Applied Spectroscopy, 1998, 52, 1383-1390.	1.2	14
129	Ferrole-estradiol complex as a test for receptor dimerization. Journal of Organometallic Chemistry, 1997, 533, 97-102.	0.8	14
130	Synthesis of 17?-ruthenocenyl-17?-oestradiol and its potential as a radiopharmaceutical agent. Applied Organometallic Chemistry, 1997, 11, 771-781.	1.7	18
131	Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chemical Communications, 1996, , 955-956.	2.2	245
132	Quantitative Analysis of Mixtures of Metal–Carbonyl Complexes by Fourier-Transform Infrared Spectroscopy: Application to the Simultaneous Double Immunoassay of Antiepileptic Drugs by the Nonisotopic Carbonyl Metalloimmunoassay Method. Analytical Biochemistry, 1996, 242, 172-179.	1.1	53
133	Analytical potential of near-infrared fourier transform Raman spectra in the detection of solid transition metal carbonyl steroid hormones. Journal of Raman Spectroscopy, 1995, 26, 31-38.	1.2	11
134	Production of specific antibodies and development of a non-isotopic immunoassay for carbamazepine by the carbonyl metallo-immunoassay (CMIA) method. Journal of Immunological Methods, 1995, 186, 195-204.	0.6	43
135	Rhenium Carbonyl Complexes of .betaEstradiol Derivatives with High Affinity for the Estradiol Receptor: An Approach to Selective Organometallic Radiopharmaceuticals. Journal of the American Chemical Society, 1995, 117, 8372-8380.	6.6	182
136	Estrogen derivatives of transition metal complexes for analytical detection enhancement. Part II. Inorganica Chimica Acta, 1994, 218, 207-210.	1.2	13
137	New applications of carbonylmetalloimmunoassay (CMIA): a non-radioisotopic approach to cortisol assay. Journal of Immunological Methods, 1994, 171, 201-210.	0.6	43
138	Synthetic strategy for organometallic complexes of rhenium with exceptionally high affinity for the oestradiol receptor; their potential use as imaging and therapeutic agents. Journal of the Chemical Society Chemical Communications, 1994, , 453-454.	2.0	34
139	Estrogen Derivatives of Transition-Metal Complexes for Analytical Detection Enhancement. Organometallics, 1994, 13, 3110-3114.	1.1	8
140	Modification of estradiol at the 17-position. Effect of changing the OH group for a transition-metal carbonyl cluster on the estradiol receptor recognition. Organometallics, 1993, 12, 4545-4552.	1.1	34
141	Synthesis of cobalt carbonyl complexes of cortisol and testosterone. Study of their recognition by specific polyclonal antibodies. Bioconjugate Chemistry, 1993, 4, 419-424.	1.8	23
142	Bioorganometallic chemistry: a future direction for transition metal organometallic chemistry?. Accounts of Chemical Research, 1993, 26, 361-369.	7.6	298
143	Molecular recognition using bioorganometallic probes: NMR, x-ray crystallographic, and molecular modeling study of the conformations of chromium tricarbonyl derivatives of hexestrol and their relevance to estradiol-receptor binding. Organometallics, 1992, 11, 4061-4068.	1.1	11
144	Carbonylmetalloimmunoassay (CMIA) a new type of non-radioisotopic immunoassay. Journal of Immunological Methods, 1992, 148, 65-75.	0.6	101

#	Article	IF	CITATIONS
145	Syntheses and affinities of novel organometallic-labeled estradiol derivatives: a structure-affinity relationship. Journal of Medicinal Chemistry, 1992, 35, 3130-3135.	2.9	76
146	Estradiols Modified by Metal Carbonyl Clusters as Suicide Substrates for the Study of Receptor Proteins: Application to the Estradiol Receptor. Angewandte Chemie International Edition in English, 1992, 31, 753-755.	4.4	49
147	Carbonylmetallclusterâ€modifizierte Östradiole als Suizidâ€&ubstrate zur Untersuchung von Rezeptorproteinen: Anwendung beim Östradiolâ€Rezeptor. Angewandte Chemie, 1992, 104, 790-792.	1.6	17
148	(N-Succinimidyl 4-pentynoate)(hexacarbonyldicobalt): a transition-metal carbonyl complex having similar uses to the Bolton-Hunter reagent. Bioconjugate Chemistry, 1991, 2, 13-15.	1.8	37
149	Fourier transform infrared spectroscopic method for the quantitative trace analysis of transition-metal carbonyl-labeled bioligands. Analytical Chemistry, 1991, 63, 2323-2329.	3.2	89
150	Vibrational spectra of the organometallic estrogen-receptor marker [3-O-(3-hydroxypropyl)-17β-estradiol]-α-tricarbonylchromium(0) and related compounds. Journal of Raman Spectroscopy, 1990, 21, 355-358.	1.2	5
151	Affinity labelling of estradiol receptor by ferrocenyl tagging of estradiol 17α-position. Journal of the Chemical Society Chemical Communications, 1990, , 837-839.	2.0	17
152	An Ultra-Low-Volume Gold Light-Pipe Cell for the IR Analysis of Dilute Organic Solutions. Applied Spectroscopy, 1990, 44, 1092-1094.	1.2	22
153	Application of Organotransition Metal Carbonyl Complexes as Infrared Markers for Hormonal Steroids in Biological Processes. Comments on Inorganic Chemistry, 1989, 8, 269-286.	3.0	30
154	The use of high affinity binding bioligands modified by transition metal carbonyl moieties. Pure and Applied Chemistry, 1989, 61, 565-572.	0.9	32
155	Cobalt and molybdenum carbonyl clusters in immunology. Synthesis and binding properties of mycotoxin derivatives of zearalenone. Journal of Organometallic Chemistry, 1989, 359, C53-C56.	0.8	18
156	Quantitative IR Analysis in the Picomole Range of Organometallic-Labeled Biomolecules in KBr Disks. Applied Spectroscopy, 1989, 43, 1497-1498.	1.2	10
157	Organometallic derivatives of estradiol as bioligands: Targetted binding of the estradiol receptor. The Journal of Steroid Biochemistry, 1989, 34, 301-305.	1.3	24
158	Transition-metal carbonyl complexes in progesterone receptor assay. Inorganic Chemistry, 1988, 27, 1850-1852.	1.9	28
159	Synthesis and receptor binding of polynuclear organometallic estradiol derivatives. The Journal of Steroid Biochemistry, 1988, 30, 301-306.	1.3	39
160	Organometallic estrogens: synthesis, interaction with lamb uterine estrogen receptor, and detection by infrared spectroscopy. Biochemistry, 1988, 27, 6659-6666.	1.2	114
161	Transition-metal carbonyl clusters as novel infrared markers for estradiol receptor site detection. Organometallics, 1987, 6, 1985-1987.	1.1	28
162	Régioselectivité de la propargylation, par des ions carbéniums organométalliques, d'aromatiques polysubstitués; application aux dérivés du zéranol. Journal of Organometallic Chemistry, 1987, 328, C12-C15.	0.8	18

#	Article	IF	CITATIONS
163	Synthesis of tritium-labeled (3)-O-(3-hydroxypropyl)-17α-estradiol chromium tricarbonyl: The first radioactive transition metal carbonyl steroid hormone. Journal of Labelled Compounds and Radiopharmaceuticals, 1987, 24, 1257-1263.	0.5	13
164	Transition metal carbonyl oestrogen receptor assay. Pure and Applied Chemistry, 1985, 57, 1865-1874.	0.9	65
165	The use of tricarbonyl chromium hexestrol derivatives in the detection of oestradiol receptor sites. Journal of the Chemical Society Chemical Communications, 1985, , 326.	2.0	9
166	Chromium tricarbonyl complexes of estradiol derivatives: differentiation of .alpha and .betadiastereoisomers using 1- and 2-dimensional NMR spectroscopy at 500 MHz. Organometallics, 1985, 4, 2143-2150.	1.1	82
167	Metal carbonyl fragments as a new class of markers in molecular biology. Journal of the American Chemical Society, 1985, 107, 4778-4780.	6.6	92
168	Stereospecific 6-alkylation of oestradiol derivatives via Cr(CO)3 complexes. Journal of the Chemical Society Chemical Communications, 1984, , 428.	2.0	22
169	Binding and effects of 5α-androstane-3β, 17β-diol in the male rat pituitary. The Journal of Steroid Biochemistry, 1983, 19, 241-246.	1.3	14
170	Doubles liaisons conjuguees avec un carbonyle. Nouveaux complexes avec Fe(CO)3PP3 Tetrahedron Letters, 1974, 15, 1499-1502.	0.7	15
171	Inhibition of Cathepsin B by Ferrocenyl Indenes Highlights a new Pharmacological Facet of Ferrocifens. European Journal of Inorganic Chemistry, 0, , .	1.0	3